Meeting
2022 ASCO Annual Meeting
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.
Presenter
Ravi Vij, MD
Washington University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04910568
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8069)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8069
Abstract #
TPS8069
Poster Bd #
491b
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.
Speaker: Sosana Delimpasi, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.
Speaker: Adam D. Cohen, MD
Videos & Slides
2023 ASCO Annual Meeting
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
Speaker: Jian-Qing Mi
Videos & Slides
2022 ASCO Annual Meeting
Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.
Speaker: Malin Hultcrantz, MD, PhD